Eli Lilly and Co's revenue for the
three
months ended in Mar. 2026 was CHF15,588 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was CHF57,625 Mil.
Eli Lilly and Co's Revenue per Share for the
three
months ended in Mar. 2026 was CHF17.40.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF64.17.
Good Sign:
Eli Lilly and Co has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Eli Lilly and Co was 48.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 31.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 20.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 13.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Eli Lilly and Co's highest 3-Year average Revenue per Share Growth Rate was 31.90% per year. The lowest was -5.70% per year. And the median was 7.40% per year.
Eli Lilly and Co (XSWX:LLY) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Eli Lilly and Co Revenue Related Terms
Eli Lilly and Co Revenue Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Revenue distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF57,625 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (XSWX:LLY) has a Revenue of CHF57,625 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Revenue too high?
Eli Lilly and Co's current Revenue is CHF57,625 Mil. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Revenue compare to JNJ and ABBV?
Eli Lilly and Co's Revenue of CHF57,625 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Revenue is CHF57,625 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,115.06, compared to a current price of CHF970.00 — trading 13% below its estimated fair value. The current Revenue is CHF57,625 Mil. Eli Lilly and Co's overall GF Score™ is 100/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Revenue is CHF57,625 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF970.00 is trading 13% below its estimated GF Value™ of CHF1,115.06.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
Revenue: CHF57,625 Mil
GF Value™: CHF1,115.06 vs. price of CHF970.00 (13% below fair value)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score
Get the complete analysis for XSWX:LLY
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
